Afimetoran Phase 2 trial delivers significant lupus improvement as Beeline Medicines eyes pivotal studies
Explore Beeline Medicines' Phase 2 afimetoran lupus results, showing a 30-point response advantage and promising potential for an oral therapy.
Pharma & Biotech